MINNEAPOLIS / Jan 29, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the American Heart Association 2024 International Stroke Conference being held in Phoenix, AZ from February 7 – 9, 2024. For information about the event, visit: https://professional.heart.org/en/meetings/international-stroke-conference.
The DiaMedica poster is:
Poster Title: “Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study To Evaluate The Safety And Efficacy Of Dm199 For The Treatment Of Acute Ischemic Stroke (ReMEDy2 Trial)”
The poster will be located in Poster Hall 5-6 (Poster Board CTP36). On Thursday February 8, 2024, from 7:00 PM – 07:30 PM. Dr. Scott Kasner, ReMEDy2 trial National Principal Investigator, will be present to answer questions about the poster. Following the session, a reprint of the poster will be accessible from DiaMedica’s website at: https://www.diamedica.com/investors/events-presentations.
DiaMedica will also be exhibiting at the conference located in the main hall at booth 1021.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.
| Last Trade: | US$7.09 |
| Daily Change: | -0.19 -2.61 |
| Daily Volume: | 504,553 |
| Market Cap: | US$366.480M |
August 12, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
